65,437 trials
Cryptogenic Stroke
Primary: Composite of Recurrent Nonfatal Ischemic Stroke, Fatal Ischemic Stroke, or Early Death After Randomization — 9; 16 Participants — p=0.08
Total Knee Replacement · Total Knee Arthroplasty · Pain
Primary: Average Knee Pain While Walking — 3.8 Scores on a scale
Anesthesia
Primary: Mean Time to Pulpal Response After Mandibular Molar Anesthesia — 99; 98 Minutes — p=0.74
Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Hodgkin Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Maximum-tolerated Dose (MTD) of Yttrium-90-BC8-DOTA — 34 Gy - MTD
Denture Cleansers
Primary: Proportion of Participants Experiencing or Reporting Treatment Emergent (TE) Oral Adverse Events (AEs) on or Before 14 Days of Use — 0.039; 0.013 Proportion of…
Anogenital Human Papilloma Virus Infection · Condyloma Acuminata
Primary: Combined Incidence of HPV Type 6, 11, 16, or 18-related Persistent Infection — 0.3; 1.9 Cases per 100 person-years of follow-up — p=<0.001
Tick Borne Encephalitis · Virus Diseases
Primary: Percentage of Subjects With Detectable TBE Antibody Titers Greater Than or Equal to (≥) 2 — 95.83; 100.0; 97.17 Percentage of subjects
Acute Otitis Media
Primary: Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) — -4.3; -5.0; -4.6; -4.9 units on a scale
Hypertension
Primary: Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC [0-t]) of Hydrochlorothiazide and Amiloride Hydrochloride — 2160; 2360…
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Type 1 Diabetes · Type 2 Diabetes
Primary: Mean Continuous Glucose Monitor (CGM) Glucose Values — 158; 174; 161; 156 mg/dl
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Percentage of Participants Who Develop Acute Graft-versus-host Disease (GVHD) — 49; 10 Participants
Melanoma
Primary: Number of Patients With Dose-limiting Toxicity (Phase I) — 0; 1; 1; 0 Participants
Cytomegalovirus Infections
Primary: Change in Sperm Density From Baseline to the End of Treatment (EOT) — -9.770; 30.396 mil/mL — p=0.0075
Breast Cancer
Primary: Number of Subjects With Acceptable Overall Clinical Image Quality for Patient-assisted (PA) and Technologist-controlled (TC) Image Sets — 30; 30 Participants